218 results on '"Rosell, R"'
Search Results
2. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
3. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
4. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
5. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
6. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
7. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
8. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
9. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies
10. 1951P A multicenter, retrospective study of non-small-cell lung carcinoma (NSCLC) harboring EGFR exon 20 insertions: Distribution, variants, and prevalence of coalterations
11. Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients
12. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study
13. The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
14. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy
15. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer
16. Interferon-gamma induction correlates with protection by DNA vaccine expressing E2 glycoprotein against classical swine fever virus infection in domestic pigs
17. Serologic and virologic investigations into pestivirus infection in wild and domestic ruminants in the Pyrenees (NE Spain)
18. 2325P Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
19. P06-23: Inhibition of DNA Repair in Non-small Cell Lung Cancer Cells: Innovative ERCC1-XPF Small Molecule Inhibitors to Enhance Cisplatin Cytotoxicity
20. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
21. 199P Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET) and V-ATPase
22. 178P Targeting XPO1-dependent nuclear export of HMGB1 in non-small cell lung cancer
23. 79TiP Progress of a phase I trial (TOTEM) of repotrectinib in combination with osimertinib in advanced, metastatic EGFR mutant NSCLC
24. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients
25. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial
26. The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer
27. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
28. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer
29. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study
30. 247 (PB027) - Preclinical studies of the bispecific MUC1xEGFR antibody drug conjugate M1231 in EGFR mutant NSCLC
31. EP16.03-003 Systematic Population-based Identification of NTRK Fusion Genes Among Hispanic Patients with Non-Small Cell Lung Cancer (NSCLC)
32. EP16.02-007 Detection of Clinically Relevant Fusions and Exon Skipping Alterations in Non Small Cell Lung Cancer Patients Liquid Biopsies
33. P08-20 Cytotoxic effects of the SOD mimic MnTnHex-2-PyP5+ and its combination with cisplatin in non-small cell lung cancer cells
34. Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
35. Influence of texture on organic matter distribution and quality and nitrogen and sulphur status in semiarid Pampean grassland soils of Argentina
36. Classification of atypical EGFR mutations in non-small-cell lung cancer
37. 233P Breast cancer organoids mimic disease heterogeneity, allow high-throughput drug screening and show correlation with clinical response
38. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study
39. A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site
40. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study
41. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
42. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors
43. P70.08 Allelic Frequencies of Population Markers Correlate with KRAS G12C Prevalence: Considerations for Ancestries and Molecular Epidemiology
44. P70.01 KRAS G12C Mutations Among NSCLC Patients Present With a High Intrerregional Variation, Indicating a Population Substructure
45. P68.05 Human Lung Carcinoma Primary Cultures From Malignant Pleural Effusions as a Tool for Drug Screening and Personalized Therapy
46. P59.14 Concordance and Performance of ddPCR Compared to NGS for The Detection of KRAS G12C Mutation
47. P59.03 Comparison of Two RNA-Based Platforms for Detection of Fusions and Met Splicing Variant in Non Small Cell Lung Cancer Samples
48. P48.09 Body Mass Index Predicts Benefit From Adding Metformin to EGFR-TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT
49. P23.02 Digital Multiplexed circRNA Analysis From Plasma-Derived Extracellular Vesicles of Lung Cancer Patients
50. P22.04 Prospective Validation of an Eight Gene mRNA Signature in Plasma for the Diagnosis of Early Stage Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.